NMN vs NR vs NAD+: The Science Behind NAD+ Decline as the Central Mechanism of Cellular Aging, Which Precursor Actually Works, and Why the Route to Your Cells Matters More Than the Dose
Updated: June 2026NMN supplement · NMN benefits · NMN longevity · NMN anti-aging · NMN vs NR · nicotinamide mononucleotide · nicotinamide riboside · NR supplement · NAD+ supplement · NAD+ longevity · NAD+ aging · how to increase NAD+ · NAD+ precursors · sirtuin activation · SIRT1 · SIRT3 · David Sinclair NMN · David Sinclair sirtuins · Lifespan book Sinclair · NMN David Sinclair protocol · Leonard Guarente NR · Charles Brenner nicotinamide riboside · NAMPT enzyme · NMN biosynthesis · NAD+ biosynthesis pathway · salvage pathway NAD+ · de novo NAD+ synthesis · tryptophan NAD+ · CD38 NAD+ consumption · CD38 and aging · NAD+ decline with age · NAD+ levels by age · PARP1 NAD+ · DNA repair NAD+ · NAD+ and DNA damage · mitochondria NAD+ · NAD+ and energy · NADH electron transport chain · NAD+/NADH ratio · Yoshino 2021 · Yoshino Science NMN insulin sensitivity · NMN clinical trial · NMN human study · NMN women prediabetes · NMN muscle · NMN insulin resistance · NR clinical trial · Bogan 2008 NR · Airhart 2017 NR heart failure · Martens 2018 NR blood pressure · NMN bioavailability · NR bioavailability · NMN vs NR absorption · sublingual NMN · liposomal NAD+ · NAD+ IV infusion · NMN dosage · NMN 500mg · NMN 1000mg · when to take NMN · NMN morning · NMN with resveratrol · pterostilbene vs resveratrol · NMN side effects · NMN safety · NMN long term · best NMN supplement · NMN Renue by Science · Tru Niagen NR · biological age test · NMN blood test · NAMPT booster · apigenin CD38 inhibitor
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in the body that participates in hundreds of metabolic reactions as an electron carrier. It is the currency of cellular energy metabolism: in its oxidized form (NAD+), it accepts electrons from metabolic processes; in its reduced form (NADH), it carries those electrons to the mitochondrial electron transport chain to generate ATP. Without adequate NAD+, mitochondria cannot produce energy, sirtuins cannot function, PARP1 enzymes cannot repair DNA, and cells cannot maintain the metabolic flexibility that characterizes biological youth.
The central aging-relevant finding of the last two decades of NAD+ research is that NAD+ levels decline dramatically with age — by approximately 50% between ages 40 and 60 in human blood and tissue, and by up to 80% in some tissues by late life. The question of why this happens, and whether it can be reversed with supplementation, has generated one of the most productive and most commercially exploited bodies of longevity research in recent years. Understanding the mechanisms behind NAD+ decline reveals both why supplementation is conceptually sound and why the current evidence for NMN and NR — while promising — is considerably more modest than the marketing suggests.
−50%
NAD+ decline by age 60 — Zhu 2015 (PNAS): measured NAD+ levels in human skin tissue across age groups; NAD+ in skin fibroblasts declined approximately 50% between young adults (20s) and older adults (60s); skeletal muscle NAD+ decline similar trajectory confirmed across multiple species and human tissue studies; blood NAD+ (whole blood): Airhart 2017 measured baseline NAD+ metabolite levels across age groups — significant decline with age; MECHANISM: two converging causes: (1) reduced biosynthesis — NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, declines with age; NAMPT converts nicotinamide → NMN → NAD+; lower NAMPT = slower NAD+ production; (2) increased consumption — CD38 (a NAD+ glycohydrolase) increases dramatically with age and with chronic inflammation; CD38 degrades NAD+ to produce cyclic ADP-ribose signaling molecules; aged tissue has substantially more CD38 activity; Camacho-Pereira 2016 (Cell Metabolism): CD38 knockout mice maintain youthful NAD+ levels into old age AND show protection from age-related metabolic decline; conclusion: NAD+ decline is not just reduced input — it is also dramatically increased destruction
Yoshino 2021
the key human NMN trial — Yoshino 2021 (Science, N=25, Washington University in St. Louis): rigorous 10-week double-blind placebo-controlled RCT in postmenopausal women with prediabetes or obesity; intervention: NMN 250mg/day vs placebo; primary outcome: muscle insulin sensitivity (hyperinsulinemic euglycemic clamp); secondary: NMN metabolite levels in blood; results: NMN supplementation significantly increased skeletal muscle insulin sensitivity vs placebo; blood NMN and NAD+ metabolite levels rose significantly (confirming oral NMN was absorbed and converted); skeletal muscle gene expression changed — genes involved in muscle remodeling, energy metabolism, and insulin signaling were upregulated; important context: insulin sensitivity improvement did NOT translate to significant improvements in blood glucose, HbA1C, or body composition in this 10-week study — these are likely longer-term outcomes; sample size was small and single-sex; BUT: this is the most rigorous human RCT demonstrating NMN bioavailability AND biological activity in human tissue — the prior key open question; prior Yoshino 2011 (Cell Metabolism): NMN in mice reversed age-associated physiological decline including energy metabolism, physical activity, insulin sensitivity, eye function, bone density, immune function — foundational animal data
Sirtuins
the NAD+-dependent longevity enzymes — sirtuins (SIRT1–7) are a family of protein deacylases that require NAD+ as a co-substrate for every reaction; they cannot function without it; sirtuin functions relevant to aging: SIRT1: activates PGC-1α (mitochondrial biogenesis); promotes autophagy; deacetylates p53 (reduces apoptosis); FOXO activation (stress resistance); SIRT3: mitochondrial maintenance; reduces ROS (reactive oxygen species); SIRT6: DNA repair (telomere maintenance); reduces inflammation via NF-κB deacetylation; SIRT7: ribosomal biogenesis; David Sinclair (Harvard): sirtuins are the linchpin of his Information Theory of Aging (Lifespan, 2019) — epigenetic noise accumulates with age as sirtuins are diverted from gene regulation to DNA repair (the "emergency response"), disrupting gene expression patterns that define cell identity; restoring NAD+ allows sirtuins to return to regulatory functions and potentially restore youthful epigenetic patterns; CAVEAT: the sirtuin→longevity→NAD+ supplementation chain is mechanistically compelling but has not been proven to extend human lifespan; the human evidence is for intermediate outcomes (insulin sensitivity, blood pressure, aerobic capacity)
NMN vs NR
the absorption debate — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are two different precursors to NAD+; the original controversy: NMN is a larger molecule than NR; the question was whether NMN could be absorbed intact or had to be first dephosphorylated to NR in the intestine before absorption; Irie 2020 (NPJ Aging): demonstrated in humans that oral NMN raises blood NMN levels directly — NMN is absorbed intact, likely via a dedicated intestinal transporter (Slc12a8, identified in mice by Grozio 2019 Nature Metabolism); NR: absorbed and phosphorylated to NMN in cells, then converted to NAD+; Trammell 2016 (Nature Communications): NR 1,000mg single dose in humans raised blood NAD+ by 2.7× within 4 hours; conversion route: NR → NMN → NAD+ (in cells); practical comparison: both appear to raise NAD+ levels in human tissue; NMN may have a slight tissue distribution advantage if the Slc12a8 transporter is active in muscle and other target tissues; NR has more published human trial data across diverse populations; neither has been proven superior in head-to-head human RCT comparing tissue NAD+ levels and functional outcomes simultaneously
Ready to build the full protocol?
The Longevity Stack ranks 20+ compounds by evidence tier — the full biomarker panel, VO2 max protocol, sleep science, hormone chapter, and three budget-level stacks, built from the same research on this page.
Get the Longevity Stack → $19
NAD+ Precursor Comparison
| Form | Route to NAD+ | Human Evidence | Cost/dose | Notes |
|---|
| NMN (oral) | Direct absorption → NMN → NAD+ in cells | Yoshino 2021 (muscle insulin sensitivity); Irie 2020 (bioavailability confirmed); multiple smaller studies | Higher than NR typically | Most heavily marketed form; Sinclair's preferred form; Slc12a8 transporter may give tissue-specific advantage |
| NR (Niagen/Tru Niagen) | NR → NMN → NAD+ in cells | Multiple human RCTs: Martens 2018 (blood pressure in older adults); Airhart 2017 (heart failure); Dellinger 2017; most robust human trial database | Moderate; Tru Niagen is the standardized commercial form | Charles Brenner (discoverer) and Leonard Guarente's preferred form; older and more human data than NMN |
| Nicotinamide (NAM) | Salvage pathway → NMN → NAD+ | High; it's a vitamin (B3); widely available and cheap; raises NAD+ at high doses | Very low — dirt cheap | Concern: at high doses (1–3g/day), NAM inhibits sirtuins (SIRT1) by product inhibition of the very enzymes you're trying to activate — counterproductive; not recommended as NAD+ precursor for longevity |
| Niacin (nicotinic acid) | De novo → NAD+ | Decades of clinical use for lipids; raises NAD+; Trammell 2016: efficient NAD+ precursor | Very low | Causes flushing (prostaglandin-mediated) that limits compliance; flush-free niacin (inositol hexaniacinate) is NOT equivalent — does not raise NAD+ |
| Sublingual NMN | Buccal absorption → bypasses first-pass | Limited comparative data; theoretically higher bioavailability than oral by bypassing gut/liver first pass | Higher (specialty products) | Some practitioners prefer this form; no direct head-to-head vs oral in humans; theoretically sound |
| IV NAD+ | Direct; bypasses all absorption barriers | Used clinically for addiction treatment; definitively raises NAD+; expensive | Very high ($150–800/session) | No longevity-specific human RCT data; reserved for clinical settings; not practical for ongoing supplementation |
NAD+ Optimization Protocol — Evidence-Based Approach
Lifestyle first (free and evidence-based for NAD+ elevation): exercise — particularly high-intensity interval training — significantly increases NAMPT expression (the rate-limiting enzyme for NAD+ synthesis); Costford 2010: NAMPT increases in skeletal muscle following exercise; this is why regular exercise is the most validated "NAD+ booster" available; fasting/caloric restriction: increases NAD+ via NAMPT upregulation and reduced CD38 activation; heat exposure (sauna): increases Hsp90 which stabilizes NAMPT; these three lifestyle interventions address NAD+ from the production side without supplements.
Supplement protocol — if adding NMN or NR: NMN: 250–500mg daily in the morning (Yoshino 2021 used 250mg; many practitioners use 500mg; going above 1,000mg/day is unsupported by human data and no evidence supports more being better); NR: 300–1,000mg daily; Tru Niagen 300mg = the validated dose from Martens 2018 and other trials; some practitioners use 300mg twice daily; timing: morning with or without food; some animal data suggests fasted morning maximizes effect but human data is insufficient to specify timing with confidence; combination with resveratrol or pterostilbene: Sinclair takes NMN + resveratrol together (personal N=1, reported publicly); resveratrol activates SIRT1 directly; pterostilbene (the methylated stilbene from blueberries) has higher bioavailability than resveratrol and similar SIRT1 activation; no human RCT has combined NMN/NR + resveratrol/pterostilbene and measured longevity outcomes — this combination is mechanistically compelling but unproven.
CD38 inhibitor strategy: since CD38 is a major driver of age-related NAD+ consumption, inhibiting CD38 may be as important as supplementing precursors; apigenin — a flavonoid found in parsley, chamomile, and celery — inhibits CD38 in vitro (Escande 2013); quercetin has similar activity; practical: parsley consumed regularly, chamomile tea, quercetin-rich foods (apples, onions, capers) may support NAD+ by reducing destruction; apigenin supplement: 50–100mg/day is used by some practitioners (Sinclair reported using apigenin); evidence in humans is weak but mechanism is sound; luteolin and kuromanin (blackcurrant) also show CD38 inhibition in vitro.
Testing NAD+ status: Jinfiniti Precision Medicine offers a blood NAD+ Intracellular Test measuring NAD+ in red blood cells; baseline is typically in the 20–40 μmol/L range; supplementation typically raises this to 40–80 μmol/L; repeat testing at 3 months post-supplementation confirms whether your specific supplement and dose is working; cost ~$100; the only validated way to know if supplementation is elevating YOUR NAD+ (response is highly individual and depends on gut microbiome, NAMPT expression, and CD38 activity).
NMN 500mg →
NAD+ Intracellular Test →
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.